Clinical trial of plasma perfusion over immobilized staphylococcal protein A in metastatic breast cancer.
Nineteen patients with metastatic breast cancer refractory to conventional therapy were treated with plasma perfusion over 200 mg of staphylococcal Protein A immobilized on a silica matrix. Fever and chills (33%), pain at the site of tumor (18%), and dyspnea (16%) were the most frequent toxic effects encountered. Four patients (21%) developed a disseminated rash which necessitated cessation of treatment. Of 16 patients evaluable for response, one achieved a minor response of chest wall disease and two had no change in hepatic metastases for 4 and 5 months' duration. Potential mechanisms of antitumor effect are discussed.
D000328:Adult; D000368:Aged; D001769:Blood; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007163:Immunosorbent Techniques; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010477:Perfusion; D013205:Staphylococcal Protein A / Q000009:adverse effects / Q000627:therapeutic use*
D013205:Staphylococcal Protein A